Similar to myeloid hematologic disorders AML and myelodysplastic syndromes (MDS), BPDCN patients acquire somatic point mutations in TET2 and TP53, ASXL1, IDH2, NRAS, and NPM1, with TET2 truncating mutations being the most prevalent and recurrent genomic alteration reported9–12. Here, IDH2 is linked to acute myeloid leukemia.